GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
2.6k
c/trialwatch·posted 2 years ago by u/rohan_steiner

am I the only one who found SURMOUNT harder than the injections

Trial Data Well Actually ×8 Long Haul ×3

Right, the SURMOUNT question again, but with numbers this time.

I have 13 data points over 18 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign.

The thing I would flag for anyone new: the effect I am describing showed up at week 34, not week 83. People give up long before the interesting part.

Interested in whether this matches other people's logs or whether I am an outlier.

2,627 up / 61 down98% upvoted46 commentsid 15azwo14 Nov 2023

46 comments

9 in this archive, depth 5

best — the order this archive was captured in

u/rohan_cardoso0 points·2 years ago

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

replysharereportpermalink
u/forest_plot_fionaMOD1 point·2 years ago

Removed a chain here. The rule is one line long and it is not negotiable.

replysharereportpermalink
u/hsa_math-19 points·2 years ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/paper_trail_paulavetting1 point·2 years ago

the 15 week readout is different from the 14 week readout

replysharereportpermalink
u/rulebook_rachaelmod · c/meta1 point·2 years ago·edited

This is correct. Discontinuation arms show the regain reality.

replysharereportpermalink
u/camila_vasquez1 point·2 years ago

Phase 2 or phase 3?

replysharereportpermalink
u/rina_sobczak1 point·2 years ago

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
[deleted]1 point·2 years ago

[deleted]

replysharereportpermalink
u/customs_seizure_sid1 point·2 years ago

Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.